Vasectomy and Prostate Cancer: What the Research Says

The current scientific consensus is that vasectomy does not meaningfully increase prostate cancer risk. Early-1990s studies suggested a small association, which raised concern at the time. Larger, better-designed studies since then have failed to confirm the link, or have shown effect sizes too small to be clinically meaningful. The American Urological Association, the American Cancer Society, and most major urology bodies do not consider vasectomy a prostate cancer risk factor. Here’s the actual history of this question, what the data shows, and where the current debate sits.

The short version

• Two 1993 papers from Harvard School of Public Health (Giovannucci et al.) suggested a modest link between vasectomy and prostate cancer risk.
• Multiple follow-up studies in the 1990s and 2000s failed to replicate the finding consistently.
• A 2014 Harvard Health Professionals study revived the question with a small increased association.
• Large pooled analyses since 2017, including a 2017 JAMA Internal Medicine study of 363,000+ men, have shown no clinically significant association.
• The AUA Vasectomy Guideline explicitly states there is insufficient evidence to consider vasectomy a prostate cancer risk factor.
• Current consensus: no causal link, or one too small to matter clinically.

The 1993 Stanford / Harvard studies that started the question

In February 1993, the Journal of the American Medical Association published two papers from the Harvard School of Public Health by Edward Giovannucci and colleagues. The first analyzed the Health Professionals Follow-up Study cohort; the second analyzed the Nurses’ Health Study (asking nurses about their husbands’ procedures). Both found modest associations between vasectomy and prostate cancer risk, with relative risks in the range of 1.5 to 1.7.

The reaction was immediate. The papers were widely covered in the press. The National Institutes of Health convened a panel to review the evidence. The panel’s 1993 conclusion was cautious: the data was not strong enough to recommend changes to vasectomy practice, but the link warranted further study.

A few methodological notes about the original studies:

• The studies were observational, not randomized. Men who choose vasectomies may differ from men who don’t in ways that could affect prostate cancer detection.
• Detection bias was a known concern. Men who get a vasectomy see urologists more frequently and may be more likely to be screened for prostate cancer.
• The effect size was modest. A relative risk of 1.5 is not dramatic, particularly for a common cancer with significant non-vasectomy-related risk factors (age, race, family history).

What happened next: a decade of mixed results

Through the 1990s and 2000s, multiple cohort and case-control studies looked at the same question with mixed results:

• Some studies replicated a modest association, particularly with longer time since vasectomy.
• Other studies, including a 2002 New Zealand cohort of over 50,000 men, found no association.
• Meta-analyses pooled the available data and produced conflicting summaries depending on which studies were included.

The accumulating evidence began to lean toward “no clinically significant link,” but the question was not settled.

The 2014 Harvard follow-up

In 2014, Mucci, Wilson, Giovannucci, and colleagues published an updated analysis of the Health Professionals Follow-up Study in the Journal of Clinical Oncology with 24 years of follow-up. They reported a small but statistically significant increase in lethal prostate cancer (RR 1.19) among men who had a vasectomy, with a larger increase (RR 2.39) among those with a vasectomy plus high PSA screening.

The 2014 paper revived the debate. It was widely covered in the press as evidence that the link was real after all. Within the urology community, however, the reaction was more measured. Three concerns:

1. The same dataset that produced the original 1993 association was being analyzed. Independent confirmation was thin.
2. The increase in overall prostate cancer was very small.
3. Confounding variables like screening intensity and lifestyle factors were difficult to fully control for.

The 2017 JAMA Internal Medicine study and modern consensus

In 2017, JAMA Internal Medicine published a large cohort study of 363,000+ men with long follow-up. The study, by Siddiqui et al., found no clinically meaningful association between vasectomy and prostate cancer overall, no increase in high-grade prostate cancer, and no increase in prostate cancer mortality.

A 2017 meta-analysis published the same year, pooling results across 53 studies and millions of patient-years, came to a similar conclusion: any association, if it exists, is too small to be clinically meaningful, and is likely explained by detection bias rather than a causal mechanism.

The AUA Vasectomy Guideline was updated to reflect this evidence and explicitly states: “There is insufficient evidence to recommend that vasectomy is a risk factor for prostate cancer or any other cancer.”

The American Cancer Society similarly does not list vasectomy among prostate cancer risk factors.

Why the original signal probably wasn’t real

Several explanations for the 1993 and 2014 findings have been proposed:

• Detection bias: men who have had a vasectomy see urologists more often and get screened more aggressively. They are more likely to have prostate cancer detected, particularly early-stage cancer, simply because they are in the system.
• Healthy user bias: men who get vasectomies are also men who get other elective medical procedures. They may have different healthcare utilization patterns that confound the association.
• Statistical noise: small effect sizes in observational studies are notoriously hard to distinguish from confounding. The 1993 finding could simply have been an artifact.
• Cohort-specific effects: the original Harvard Health Professionals cohort was largely white, educated, middle-aged American men. Generalization to other populations is uncertain.

None of these definitively explain the 1993 result, but together they provide a plausible non-causal explanation. The more important point is that subsequent studies in larger, more diverse populations have not consistently confirmed the original signal.

What this means for an individual decision

If you are considering a vasectomy and are worried about prostate cancer, the current evidence does not justify that concern. Major urology bodies, including the AUA, do not consider vasectomy a prostate cancer risk factor. Your prostate cancer risk is determined by:

• Age (risk increases steeply after 50)
• Race (higher risk in Black men)
• Family history (first-degree relatives with prostate cancer raise risk substantially)
• Certain genetic syndromes (BRCA1/2, Lynch syndrome)
• Diet and lifestyle factors (modest effects, contested)

These factors dominate the risk calculation. Vasectomy does not appear on the list. Your screening recommendations and risk-reduction strategies are the same whether you’ve had a vasectomy or not.

If you have a strong family history of prostate cancer, talk to your urologist about screening on its own merits. If you don’t, follow standard screening recommendations starting in your 50s (earlier for high-risk groups). Your vasectomy status doesn’t change that conversation.

What about other cancers?

Various studies have looked at vasectomy and risk of testicular cancer, melanoma, lymphoma, and a handful of other cancers. The pattern is similar: occasional small associations in some studies, no consistent replication, and no causal mechanism that holds up to scrutiny.

The AUA Guideline language covers all of this: insufficient evidence that vasectomy increases cancer risk of any type. No major urology, oncology, or public health body considers vasectomy a cancer risk factor in 2026.

What screening looks like if you have had a vasectomy

The same as it would be otherwise. Standard prostate cancer screening discussions:

• Most major bodies recommend men discuss PSA screening with their doctor starting at age 50 for average-risk men.
• Black men and men with a first-degree relative with prostate cancer should discuss screening earlier, often at 40 to 45.
• Men with hereditary syndromes (BRCA1/2, Lynch) should follow their genetic counselor’s specific recommendations.

Vasectomy is not on this list. Your urologist does not need to screen you more aggressively or earlier because of a vasectomy.

FAQ

Did the original 1993 studies definitively show a vasectomy-prostate cancer link?

No. They showed a modest association in observational data. Association in observational data is not the same as a causal link. Subsequent studies have largely failed to confirm the finding, and the current consensus is that any effect is too small to be clinically meaningful and is likely explained by detection bias.

Does the AUA recommend any changes in screening for men who have had a vasectomy?

No. The AUA Vasectomy Guideline does not recommend any special screening protocol based on vasectomy status. Standard age- and risk-based screening applies.

What about the 2014 Harvard study showing higher lethal prostate cancer risk?

The 2014 study reported a modest increased relative risk for lethal prostate cancer (RR 1.19). The findings have not been consistently replicated in larger or more diverse cohorts. The 2017 JAMA Internal Medicine study of 363,000+ men found no clinically significant association.

Is the timing of the vasectomy a factor?

Some studies have suggested the modest association, where present, is larger for vasectomies performed at older ages or with longer time since vasectomy. The signals are inconsistent and may reflect screening patterns rather than biology.

Should men with a family history of prostate cancer avoid vasectomies?

Not on cancer-risk grounds. A family history of prostate cancer raises baseline risk meaningfully, but adding a vasectomy on top does not, based on current evidence, further raise that risk. The discussion to have is about prostate cancer screening, not about whether to have a vasectomy.

Does vasectomy affect prostate-specific antigen (PSA) levels?

There is no consistent evidence that vasectomy affects PSA levels. Some studies have looked at short-term post-vasectomy PSA fluctuations and found small transient changes, but these do not persist and do not affect screening interpretation in the long term.

What’s the bottom line for a man considering a vasectomy?

Prostate cancer risk is not a meaningful argument against having a vasectomy. The evidence does not support a clinically significant association. If you have other reasons to be cautious (family history, BRCA status, etc.), discuss them with your urologist on their own merits, not as vasectomy-specific concerns.

Could future research change this picture?

It’s possible but unlikely. The question has been studied extensively, and the largest and most rigorous studies have not confirmed a meaningful association. Future research could refine the picture for specific subgroups (high-risk genetic backgrounds, for example), but the broad conclusion is unlikely to flip.

Sources

• American Urological Association Vasectomy Guideline (2012, amended 2015). Explicitly states insufficient evidence to consider vasectomy a prostate cancer risk factor.
• American Cancer Society: Prostate Cancer Risk Factors. Does not list vasectomy.
• JAMA Internal Medicine: Vasectomy and Risk of Prostate Cancer (2017). Large cohort study finding no clinically significant association.
• Cleveland Clinic: Vasectomy. Patient-education page.
• Mayo Clinic: Vasectomy. Procedure overview.

Editorial and informational. Not medical advice. Read the full disclaimer.